Last Updated: 13 Sep 2024
Executive Summary
Viridian Therapeutics Inc. (VRDN) is a biotechnology company focused on developing treatments for serious illnesses. The company's market capitalization is $1.265 billion, and its latest stock price is $20.7. Viridian Therapeutics has a strong analyst rating, with 7 analysts recommending a strong buy and 8 recommending a buy. The company's trailing PE ratio is negative, and its forward PE ratio is not available. Viridian Therapeutics has a price-to-sales ratio of 4392.43, a price-to-book ratio of 3.838, and an EV-to-revenue ratio of 3174.73. The company's beta is 1.067.
Company Overview
Viridian Therapeutics is headquartered in Boulder, Colorado. The company develops treatments for patients with serious illnesses, including cancer, autoimmune diseases, and infectious diseases. Viridian Therapeutics' lead product candidate is VRDN-001, a novel therapy for the treatment of acute myeloid leukemia (AML). VRDN-001 is currently in Phase 2 clinical trials.
Fundamental Analysis
Viridian Therapeutics' financial performance has been mixed in recent quarters. The company's revenue has grown in recent quarters, but its losses have also widened. In the most recent quarter, Viridian Therapeutics reported a loss of $250.2 million on revenue of $288,000. The company's gross profit margin was -34.4%, and its operating margin was -1002.6%.
Viridian Therapeutics' balance sheet is strong. The company has $437.5 million in cash and equivalents and no debt. The company's book value is $5.16 per share.
Technical Analysis
Viridian Therapeutics' stock price has been trending higher in recent months. The stock is currently trading above its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is 58.7, which indicates that the stock is overbought.
Short Term Outlook
Viridian Therapeutics' stock price is likely to continue to trend higher in the short term. The stock is currently trading above its key moving averages, and the RSI is overbought. This indicates that the stock is in a bullish trend.
Long Term Outlook
Viridian Therapeutics' long-term outlook is positive. The company has a strong pipeline of product candidates, and its financial performance is improving. The company is also well-positioned to benefit from the growing demand for treatments for serious illnesses.
Analyst Recommendations
The majority of analysts recommend buying Viridian Therapeutics stock. The company has a strong analyst rating, with 7 analysts recommending a strong buy and 8 recommending a buy. The average analyst target price is $37.81.
